These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Manipulation of the cholinergic system. Geroldi C; Bianchetti A; Trabucchi M Funct Neurol; 1997; 12(3-4):187-91. PubMed ID: 9218975 [No Abstract] [Full Text] [Related]
4. The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. Mesulam MM Prog Brain Res; 1996; 109():285-97. PubMed ID: 9009717 [No Abstract] [Full Text] [Related]
5. Reductions in acetylcholine and nicotine binding in several degenerative diseases. Whitehouse PJ; Martino AM; Marcus KA; Zweig RM; Singer HS; Price DL; Kellar KJ Arch Neurol; 1988 Jul; 45(7):722-4. PubMed ID: 3390025 [TBL] [Abstract][Full Text] [Related]
6. Nicotinic receptor abnormalities in Alzheimer's disease. Court J; Martin-Ruiz C; Piggott M; Spurden D; Griffiths M; Perry E Biol Psychiatry; 2001 Feb; 49(3):175-84. PubMed ID: 11230868 [TBL] [Abstract][Full Text] [Related]
7. [Study on Alzheimer's disease and the animal disease model--special reference to acetylcholinergic system]. Ueki A; Taira H; Miyoshi I Seishin Shinkeigaku Zasshi; 1989; 91(10):736-50. PubMed ID: 2626496 [No Abstract] [Full Text] [Related]
8. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Araujo DM; Lapchak PA Neuroscience; 1994 Aug; 61(4):745-54. PubMed ID: 7838374 [TBL] [Abstract][Full Text] [Related]
9. Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. Perry EK; Curtis M; Dick DJ; Candy JM; Atack JR; Bloxham CA; Blessed G; Fairbairn A; Tomlinson BE; Perry RH J Neurol Neurosurg Psychiatry; 1985 May; 48(5):413-21. PubMed ID: 3998751 [TBL] [Abstract][Full Text] [Related]
10. CRH defects in Alzheimer's and other neurologic diseases. de Souza EB Hosp Pract (Off Ed); 1988 Sep; 23(9):59-71. PubMed ID: 2901426 [No Abstract] [Full Text] [Related]
11. Alzheimer's disease and the cytoskeleton. Weber M Biochimie; 1986 Apr; 68(4):593-5. PubMed ID: 2427126 [No Abstract] [Full Text] [Related]
12. Nerve growth factor pharmacology: application to the treatment of cholinergic neurodegeneration in Alzheimer's disease. Lapchak PA Exp Neurol; 1993 Nov; 124(1):16-20. PubMed ID: 8282073 [TBL] [Abstract][Full Text] [Related]
13. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. Nordberg A; Alafuzoff I; Winblad B J Neurosci Res; 1992 Jan; 31(1):103-11. PubMed ID: 1613816 [TBL] [Abstract][Full Text] [Related]
16. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Dani JA; Bertrand D Annu Rev Pharmacol Toxicol; 2007; 47():699-729. PubMed ID: 17009926 [TBL] [Abstract][Full Text] [Related]
17. Is the loss of cerebral cortical choline acetyl transferase activity in Alzheimer's disease due to degeneration of ascending cholinergic nerve cells. Mann DM; Yates PO J Neurol Neurosurg Psychiatry; 1982 Oct; 45(10):936. PubMed ID: 7143014 [No Abstract] [Full Text] [Related]
18. Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer's disease. Evidence from rapid autopsy studies. Slotkin TA; Nemeroff CB; Bissette G; Seidler FJ J Clin Invest; 1994 Aug; 94(2):696-702. PubMed ID: 8040324 [TBL] [Abstract][Full Text] [Related]
19. The pathophysiology of dementia. Plum F Gerontology; 1986; 32 Suppl 1():67-72. PubMed ID: 3732820 [TBL] [Abstract][Full Text] [Related]
20. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Aucoin JS; Jiang P; Aznavour N; Tong XK; Buttini M; Descarries L; Hamel E Neuroscience; 2005; 132(1):73-86. PubMed ID: 15780468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]